Top

International Journal of Colorectal Disease

Published in:

01-12-2020 | Soft Tissue Sarcoma | Original Article

Surgical resection improves overall survival of patients with small bowel leiomyosarcoma

Authors: Vanessa M. Welten, Adam C. Fields, Pamela W. Lu, James Yoo, Joel E. Goldberg, Jennifer Irani, Ronald Bleday, Nelya Melnitchouk

Published in: International Journal of Colorectal Disease | Issue 12/2020

Abstract

Purpose

Small bowel leiomyosarcoma (SB LMS) is a rare disease with few studies characterizing its outcomes. This study aims to evaluate surgical outcomes for patients with SB LMS.

Methods

The National Cancer Database was queried from 2004 to 2016 to identify patients with SB LMS who underwent surgical resection. The primary outcome was overall survival.

Results

A total of 288 patients with SB LMS who had undergone surgical resection were identified. The median age was 63, and the majority of patients were female (56%), White (82%), and had a Charlson comorbidity score of zero (76%). Eighty-one percent of patients had negative margins following surgical resection. Fourteen percent of patients had metastatic disease at the time of diagnosis. Nineteen percent of patients received chemotherapy and 3% of patients received radiation. One-year overall survival was 77% (95% CI: 72–82%) and 5-year overall survival was 43% (95% CI: 36–49%). Higher grade (HR: 1.98, 95% CI: 1.10–3.55, p = 0.02) and metastatic disease at diagnosis (HR: 2.57, 95% CI: 1.45–4.55, p = 0.001) were independently associated with higher risk of death.

Conclusion

SB LMS is a rare disease entity, with treatment centering on complete surgical resection. Our results demonstrate that overall survival is higher than previously thought. Timely diagnosis to allow for complete surgical resection is key, and investigation into the possible role of chemotherapy or radiation therapy is needed.

Aggarwal G, Sharma S, Zheng M, Reid MD, Crosby JH, Chamberlain SM, Nayak-Kapoor A, Lee JR (2012) Primary leiomyosarcomas of the gastrointestinal tract in the post-gastrointestinal stromal tumor era. Ann Diagn Pathol 16(6):532–540. https://doi.org/10.1016/j.anndiagpath.2012.07.005CrossRefPubMed

Guzel T, Mech K, Mazurkiewicz M, Dabrowski B, Lech G, Chaber A, Slodkowski M (2016) A very rare case of a small bowel leiomyosarcoma leading to ileocaecal intussusception treated with a laparoscopic resection: a case report and a literature review. World J Surg Oncol 14(1):48. https://doi.org/10.1186/s12957-016-0798-4CrossRefPubMedPubMedCentral

Howe JR, Karnell LH, Scott-Conner C (2001) Small bowel sarcoma: analysis of survival from the National Cancer Data Base. Ann Surg Oncol 8(6):496–508. https://doi.org/10.1007/s10434-001-0496-4CrossRefPubMed

Weiss NS, Yang CP (1987) Incidence of histologic types of cancer of the small intestine. J Natl Cancer Inst 78(4):653–656PubMed

Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J (2006) Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 101(12):2826–2832. https://doi.org/10.1111/j.1572-0241.2006.00854.xCrossRefPubMed

Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS (2009) Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 249(1):63–71. https://doi.org/10.1097/SLA.0b013e31818e4641CrossRefPubMed

Hatzaras I, Palesty JA, Abir F, Sullivan P, Kozol RA, Dudrick SJ, Longo WE (2007) Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry. Arch Surg 142(3):229–235. https://doi.org/10.1001/archsurg.142.3.229CrossRefPubMed

Arts R, Bosscha K, Ranschaert E, Vogelaar J (2012) Small bowel leiomyosarcoma: a case report and literature review. Turk J Gastroenterol 23(4):381–384. https://doi.org/10.4318/tjg.2012.0406CrossRefPubMed

Tolman CJ (2017) A rare case of small bowel leiomyosarcoma presenting with acute gastro-intestinal bleeding. BJR Case Rep 3(2):20160089. https://doi.org/10.1259/bjrcr.20160089CrossRefPubMed

10.

Luis J, Ejtehadi F, Howlett DC, Donnellan IM (2015) Leiomyosarcoma of the small bowel: report of a case and review of the literature. Int J Surg Case Rep 6C:51–54. https://doi.org/10.1016/j.ijscr.2014.11.009CrossRefPubMed

11.

Stor Z, Hanzel J (2019) Ileal leiomyosarcoma presenting with intussusception. J Surg Case Rep 2019(2):rjz052. https://doi.org/10.1093/jscr/rjz052CrossRefPubMedPubMedCentral

12.

Noureldine OH, Bokhari AA, El-Tinay OF (2005) Leiomyosarcoma of the small intestine presenting as intussusception. Saudi J Gastroenterol 11(3):170–172. https://doi.org/10.4103/1319-3767.33321CrossRefPubMed

13.

Blanchard DK, Budde JM, Hatch GF 3rd, Wertheimer-Hatch L, Hatch KF, Davis GB, Foster RS Jr, Skandalakis JE (2000) Tumors of the small intestine. World J Surg 24(4):421–429. https://doi.org/10.1007/s002689910067CrossRefPubMed

14.

Talamonti MS, Goetz LH, Rao S, Joehl RJ (2002) Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 137(5):564–570; discussion 570-561. https://doi.org/10.1001/archsurg.137.5.564CrossRefPubMed

15.

Farhat MH, Shamseddine AI, Barada KA (2008) Small bowel tumors: clinical presentation, prognosis, and outcome in 33 patients in a tertiary care center. J Oncol 2008:212067. https://doi.org/10.1155/2008/212067CrossRefPubMedPubMedCentral

16.

AJCC (2018) AJCC cancer staging manual, eighth edition. Eighth edn., Chicago

17.

NCCN (2020) Soft tissue sarcoma. NCCN Clinical Practice Guidelines in Oncology

18.

Winchester DP, Stewart AK, Phillips JL, Ward EE (2010) The national cancer data base: past, present, and future. Ann Surg Oncol 17(1):4–7. https://doi.org/10.1245/s10434-009-0771-3CrossRef

19.

ACS National Cancer Database - About the National Cancer Database. American Cancer Society. Accessed June 1st 2019

20.

Raval MV, Bilimoria KY, Stewart AK, Bentrem DJ, Ko CY (2009) Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol 99(8):488–490. https://doi.org/10.1002/jso.21173CrossRefPubMed

21.

ACS National Cancer Database - Participant User Files. American College of Surgeons. https://www.facs.org/quality-programs/cancer/ncdb/puf. 2020

22.

WHO (2013) International Classification of Diseases For Oncology. Third edn., Geneva

23.

Evans HL (1985) Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 56(9):2242–2250. https://doi.org/10.1002/1097-0142(19851101)56:9<2242::aid-cncr2820560918>3.0.co;2-5CrossRefPubMed

24.

Thiels CA, Bergquist JR, Krajewski AC, Lee HE, Nelson H, Mathis KL, Habermann EB, Cima RR (2017) Outcomes of primary colorectal sarcoma: a National Cancer Data Base (NCDB) review. J Gastrointest Surg 21(3):560–568. https://doi.org/10.1007/s11605-016-3347-0CrossRefPubMed

25.

Turan M, Karadayi K, Duman M, Ozer H, Arici S, Yildirir C, Kocak O, Sen M (2010) Small bowel tumors in emergency surgery. Ulus Travma Acil Cerrahi Derg 16(4):327–333PubMed

26.

van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS, European Organisation for R, Treatment of Cancer Soft T, Bone Sarcoma G (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 Suppl 5:S83–S87. https://doi.org/10.1016/s0959-8049(02)80608-6CrossRefPubMed

27.

Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group Intergroup Adjuvant GST (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104. https://doi.org/10.1016/S0140-6736(09)60500-6CrossRefPubMedPubMedCentral

28.

Bitz U, Pink D, Busemann C, Reichardt P (2011) Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS). J Clin Oncol 29(15_suppl):10094–10094. https://doi.org/10.1200/jco.2011.29.15_suppl.10094CrossRef

29.

Jebsen NL, Bruland OS, Eriksson M, Engellau J, Turesson I, Folin A, Trovik CS, Hall KS (2011) Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall. Int J Radiat Oncol Biol Phys 81(5):1359–1366. https://doi.org/10.1016/j.ijrobp.2010.07.037CrossRefPubMed

30.

Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ, Gronchi A, Tissue ES, Bone Sarcoma G (2019) The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer 109:51–60. https://doi.org/10.1016/j.ejca.2018.12.009CrossRefPubMed

31.

Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27(25):4188–4196. https://doi.org/10.1200/JCO.2008.21.0088CrossRefPubMed

32.

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20(12):2824–2831. https://doi.org/10.1200/JCO.2002.11.050CrossRefPubMed

33.

Hensley ML, Anderson S, Soslow R, Antonescu C, Upham T, Riedel E, Aghajanian C, Maki RG (2004) Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies: report of an expanded phase II trial. J Clin Oncol 22(14_suppl):9010–9010. https://doi.org/10.1200/jco.2004.22.90140.9010CrossRef

34.

D’Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litiere S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A, European Organization for R, Treatment of Cancer Soft T, Bone Sarcoma G (2020) Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer 126(11):2637–2647. https://doi.org/10.1002/cncr.32795CrossRefPubMed

35.

Ecker BL, Peters MG, McMillan MT, Sinnamon AJ, Zhang PJ, Kelz RR, Roses RE, Drebin JA, Fraker DL, Karakousis GC (2017) Implications of lymph node evaluation in the management of resectable soft tissue sarcoma. Ann Surg Oncol 24(2):425–433. https://doi.org/10.1245/s10434-016-5641-1CrossRefPubMed

Title: Surgical resection improves overall survival of patients with small bowel leiomyosarcoma
Authors: Vanessa M. Welten
Adam C. Fields
Pamela W. Lu
James Yoo
Joel E. Goldberg
Jennifer Irani
Ronald Bleday
Nelya Melnitchouk
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Soft Tissue Sarcoma
Sarcoma
Gastrointestinal Stromal Tumor
Cytostatic Therapy
Published in: International Journal of Colorectal Disease / Issue 12/2020
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-020-03718-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Surgical resection improves overall survival of patients with small bowel leiomyosarcoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2020

Endoscopic management versus transanal surgery for early primary or early locally recurrent rectal neoplasms—a systematic review and meta-analysis

Anorectal angle at rest predicting successful sacral nerve stimulation in idiopathic fecal incontinence—a cohort analysis

Unexplained systemic inflammatory response following ileostomy closure after ileal pouch-anal anastomosis: a deeper dive into a rare entity

What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?

Update on risk factors of surgical site infection in colorectal cancer: a systematic review and meta-analysis

Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301)